This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone Sep 2026 quarter: nil revenue vs Rs 7.46 lakh; loss Rs 6.22 lakh vs profit Rs 2.10 lakh
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone quarter ended September 2026: operating revenue was nil versus Rs 7.46 lakh a year earlier, and profit after tax was a loss of Rs 6.22 lakh versus profit of Rs 2.10 lakh. Standalone half-year: revenue Rs 7.46 lakh; loss after tax Rs 4.12 lakh. Limited review was qualified over GST registration inactive from May 29, 2026 and missing GST records. Half-year operating cash outflow: Rs 63,180. Prior-period figures were regrouped.
The loss, nil revenue, qualified review and operating cash outflow raise financial risk and may pressure the share price.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹0.00 Cr | ₹0.53 Cr | −100.0% |
| Operating profit | −₹0.06 Cr | ₹0.10 Cr | −163.6% |
| Profit after tax | −₹0.06 Cr | ₹0.10 Cr | −163.6% |
| EBITDA margin | — | 18.7% | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.